CCPG1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line, featuring targeted disruption of the CCPG1 gene. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, producing a heterogeneous pool of edited cells that enables functional studies of CCPG1 in a gastric cancer context without monoclonal selection. The product is shipped as a polyclonal population, offering immediate utility for assays requiring genetic perturbation of CCPG1 while retaining the native heterogeneity of the AGS background, making it suitable for cell cycle research, proliferation analyses, and drug response profiling.
The AGS cell line is a well-established model of human gastric adenocarcinoma, originally isolated from a patient with poorly differentiated gastric carcinoma. These epithelial cells exhibit characteristics of advanced gastric cancer, including dysregulated growth signaling and aberrant cell cycle control, providing a pathologically relevant system for investigating molecular mechanisms of gastric tumorigenesis. AGS cells are widely employed for studies of signal transduction, drug sensitivity, and tumor suppressor pathways, particularly those involving p53 and CDK regulators. Their robust growth in vitro and amenability to standard cell culture techniques facilitate reproducible experimental workflows.
CCPG1 functions as a cell cycle regulator by binding and inhibiting CDK2, a key kinase that drives G1/S transition and cell cycle progression through its association with Cyclin E. CCPG1 is transcriptionally regulated by p53 and is activated by growth factor signaling pathways, positioning it as a critical node in the p53-mediated cell cycle arrest network. Mechanistically, CCPG1 interacts with CDK2 and Cyclin E complexes, repressing their kinase activity and thereby blocking phosphorylation of downstream targets required for S-phase entry. In the broader signaling landscape, CCPG1 operates within a pathway that includes p53, p21, CDK2, and Cyclin E, where it acts as a brake on proliferation. Disruption of CCPG1 relieves this inhibition, potentially leading to unchecked CDK2 activity and accelerated cell cycle progression.
In the AGS gastric adenocarcinoma model, knockout of CCPG1 abrogates its inhibitory control over CDK2, mimicking a condition frequently observed in gastric cancers where cell cycle restraints are compromised. This cell model thus provides a powerful tool for dissecting the role of CCPG1 in restraining proliferation in gastric cancer cells, where p53 pathway perturbations and dysregulated CDK2 activity are common. By comparing knockout and wild-type AGS cells, researchers can evaluate the contribution of CCPG1 to p53-dependent cell cycle arrest, assess its impact on tumor cell growth kinetics, and explore synthetic lethal interactions or drug sensitivities that arise from loss of this regulatory mechanism. The model is particularly relevant for studying mechanisms of CDK inhibitor resistance in gastric cancer.
Typical research applications of CCPG1 Knockout AGS Polyclonal Cells include cell cycle analysis via flow cytometry, gastric cancer proliferation studies using MTT or BrdU assays, and drug target validation for CDK inhibitors. The polyclonal knockout pool is suitable for co-immunoprecipitation experiments to confirm disrupted CCPG1-CDK2 interactions, western blotting to monitor downstream markers like Cyclin E and phosphorylated CDK substrates, and drug sensitivity screenings to identify compounds that selectively affect CCPG1-deficient cells. Researchers may also employ this model in high-content imaging assays or RNA sequencing to uncover global transcriptional changes upon CCPG1 loss. For additional information or to request a custom quote, please contact Ascent Research.
